MUC1/Y plasmids as tumor vaccine in the experimental study of anti-tumor roles in the bladder cancer
LUO Gang,ZHOU Si-wei,LI Zhi-jian,LI Wei,ZHOU Hua-kuo,Huang Hong-xing,GAO Xin
DOI: https://doi.org/10.3969/j.issn.1672-2019.2007.10.005
2007-01-01
Abstract:[Objective] To study the roles of the DNA vaccine containing human mucins gene in the fields of inducing specific cytotoxic T lymphocytes (CTL) and humoral immune response, so that the basic experimental data can be provided for the clinic application of human bladder cancer vaccine. [Methods] The pEGFP-C3-MUC1/Y plasmids was used to immunize male BALB/c mice. Subsequently, the production of anti-MUC1/Y antibody, IL-2 and IFN-γ were examined by ELISA. Also, the specific killing of CTL targeting to BIU-87 cell was examined by LDH release method. [Results] The production of antibodies against MUC1/Y rose and the levels of IL-2 and IFN-γ increased after immunization with the plasmids as compared with those of control groups. When the rate of effector cells to target cells were 100∶1, 50∶1, 25∶1 and 12.5∶1, the specific lysis in pEGFP-C3-MUC1/Y groups reached 50.9%, 45.9%, 47.5%, 18.6%, while control groups 18.3%, 10.7% 13.8%, 6.3%; 16.5%, 11.9%, 8.6%, 10.3%, respectively. The former group was different significantly from the later two groups (P <0.01). [Conclusions] The constructed DNA vaccines can induce the productivity of antibody against human bladder cancer mucins, as well as the CTL capable of killing the target cells expressing MUC1/Y. The study supports the application of MUC1/Y vaccine in the therapy of human bladder cancer.